AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) in adults with advanced or unresectable hepatocellular carcinoma (HCC).
The decision marks the first NICE approval of a dual immunotherapy for liver cancer in the UK.
The recommendation is based on data from the HIMALAYA phase 3 trial, which evaluated the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab). The study showed a statistically significant improvement in overall survival compared to sorafenib.
Eligible patients across England and Wales will now have access to the STRIDE regimen, offering improved long-term survival outcomes in a disease area with limited treatment options.
HCC accounts for over 75% of primary liver cancer cases in the UK. Liver cancer has the fastest-rising incidence among the 20 most common cancers, yet 70% of cases are diagnosed at an advanced stage.
Tom Keith Roach, AstraZeneca, said: “This is a positive step forward for people with advanced liver cancer and the first time this kind of immunotherapy combination will be available for these patients, showing a significant improvement in the number of patients living for five years or longer.”
Dr David J Pinato, Imperial College London, said: “This new immunotherapy combination addresses one of the most critical unmet needs in advanced liver cancer. Having access to a treatment that can deliver improved long-term survival is a major step forward for both clinicians and patients.”
Vanessa Hebditch, British Liver Trust, said: “This decision by NICE brings an important new treatment option to patients with advanced liver cancer. Access to new treatments such as this immunotherapy combination can make a real difference to patients and their families.”
